The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

THOUSAND OAKS, CA — Treating statin-intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL-cholesterol levels, according to the top-line results of the GAUSS-2 study ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

The VESALIUS-CV trial, published in JAMA and presented at ACC 2026 as a late-breaking abstract, marks a significant expansion ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

WASHINGTON, DC (UPDATED)—The eagerly anticipated final results of FOURIER, a large clinical trial testing evolocumab (Repatha, Amgen) in patients with stable atherosclerotic cardiovascular disease, ...

(HealthDay News) — Evolocumab shows promise for patients with heterozygous or homozygous familial hypercholesterolemia, according to two studies published online October 1 in The Lancet. Frederick J.

Please provide your email address to receive an email when new articles are posted on . “We designed the EBBINGHAUS study ... to assess the following hypothesis: [Did] the addition of evolocumab to ...

Data presented at the American College of Cardiology’s 63rd Annual Scientific Session showed that evolocumab (Amgen) significantly reduced low-density lipoprotein (LDL) cholesterol as an add-on to ...

Please provide your email address to receive an email when new articles are posted on . MUNICH — Adults with metabolic syndrome assigned to treatment with the PCSK9 inhibitor evolocumab experienced a ...

CHICAGO -- Among patients with very high LDL levels and confirmed muscle-related statin intolerance, evolocumab (Repatha) appears to achieve greater reductions in LDL cholesterol levels than ezetimibe ...